Clinical trial NCT03346512: Considerations on the Transfusion Threshold in Cardiac Surgery
Official title: Considerations on the Transfusion Threshold in Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Surgery
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 852
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015

Brief summary: This is a retrospective observational study of the transfusion threshold in cardiac surgery.

There is controversy in the literature regarding the transfusion threshold to be adopted, especially in a patient who has undergone cardiac surgery. Some authors suggest that the transfusion should be done in a restrictive way when a certain threshold in hemoglobin is reached, in order to avoid the risks it implies, especially infectious.This threshold is very controversial and remains to be defined (variations in the literature from 7g / dL to 9g / dL). Other authors conclude that there is no superiority of a restrictive transfusion compared to a more liberal transfusion, with regard to the morbidity or medical costs.

It is therefore interesting to study, in a retrospective manner, the global and multidisciplinary management of patients who have undergone a cardiac surgery within the CHU Brugmann hospital, to analyze if they have been adequately transfused.


Eligibility criteria: Inclusion Criteria:

- Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Hemoglobin rate
timeFrame: Baseline (just before cardiac surgery)
measure: Hemoglobin rate
timeFrame: One day after surgery (J1)
measure: Hemoglobin rate
timeFrame: Two days after surgery (J2)
measure: Hemoglobin rate
timeFrame: Five days after surgery (J5)
measure: Hematocrit rate
timeFrame: Baseline (just before cardiac surgery)
measure: Hematocrit rate
timeFrame: One day after surgery (J1)
measure: Hematocrit rate
timeFrame: Two days after surgery (J2)
measure: Hematocrit rate
timeFrame: Five days after surgery (J5)
measure: International Normalized Ratio (INR)
timeFrame: Baseline (just before cardiac surgery)
measure: International Normalized Ratio (INR)
timeFrame: One day after surgery (J1)
measure: International Normalized Ratio (INR)
timeFrame: Two days after surgery (J2)
measure: International Normalized Ratio (INR)
timeFrame: Five days after surgery (J5)
measure: Creatinin rate
timeFrame: Baseline (just before cardiac surgery)
measure: Creatinin rate
timeFrame: One day after surgery (J1)
measure: Creatinin rate
timeFrame: Two days after surgery (J2)
measure: Creatinin rate
timeFrame: Five days after surgery (J5)
measure: Total amount of blood perfusions
timeFrame: Five days after surgery (J5)
measure: Liquid balance
timeFrame: One day after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
Study officials:
affiliation: CHU Brugmann
name: Kenza Bradly, MD
role: PRINCIPAL_INVESTIGATOR
References: